2024
The Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study
Mark J, Colombo R, Alfonso C, Llanos A, Collado E, Larned J, Giese G, Dyal M, Nanna M, Damluji A. The Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study. JACC Advances 2024, 3: 101358. PMID: 39600986, PMCID: PMC11588852, DOI: 10.1016/j.jacadv.2024.101358.Peer-Reviewed Original ResearchAdverse cardiovascular eventsCatheter ablationAtrial fibrillationCardiovascular eventsHeart failureFrail patientsHospital lengthNonfrail patientsReducing major adverse cardiovascular eventsAssociated with worse outcomesMajor adverse cardiovascular eventsReduced ejection fractionHospital length of stayIn-hospital mortalityLonger hospital lengthAssociated with increased oddsDischarge dispositionInfluence of frailtyMultivariate regression analysisNationwide Inpatient SampleImpact of frailtyLength of stayPrevalence of frailtyEjection fractionJohns Hopkins Adjusted Clinical GroupsMortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis
Y K, Lee P, Chowdhury I, Schwartz R, Kang Y, Mangalesh S, Babapour G, Akman Z, Chang Y, Song J, Lessa Y, Damluji A, Nanna M, Nanna M. Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis. European Heart Journal 2024, 45: ehae666.1640. DOI: 10.1093/eurheartj/ehae666.1640.Peer-Reviewed Original ResearchRandomized controlled trialsReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitReduced EFMeta-regressionEF patientsPreserved EFBB usersReperfusion eraMeta-analysisSubgroup analysisSystematic reviewPost-MIPost-MI careEffect of beta-blockersIncreased all-cause mortalityHistory of HFEvent-free periodAll-cause mortalityTemporal trendsStudy inclusion periodModern randomized controlled trialsBeta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis
Chi K, Lee P, Chowdhury I, Akman Z, Mangalesh S, Song J, Satish V, Babapour G, Kang Y, Schwartz R, Chang Y, Borkowski P, Nanna M, Damluji A, Nanna M. Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis. European Journal Of Preventive Cardiology 2024, zwae298. PMID: 39298680, DOI: 10.1093/eurjpc/zwae298.Peer-Reviewed Original ResearchReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitBB useReduced EFCV mortalityPost-MIRandom-effects meta-analysisMeta-analysisHistory of HFAll-cause mortalityTemporal trendsPrespecified subgroup analysesEvent-free periodCardiovascular (CVIncreased CV mortalityStudy inclusion periodPost-myocardial infarctionContemporary dataAssociated with detrimental effectsNon-significant trendSecondary preventionBB users
2022
Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trials